Special Issue "Wound Healing Potential of Marine Natural Products"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 8285

Special Issue Editor

Dr. Soo-Jin Heo
E-Mail Website
Guest Editor
Jeju Marine Research Center, Korea Institute of Ocean Science and Technology (KIOST), Jeju 63349, Korea
Interests: marine organisms; marine natural products; functional foods; cosmeceutical materials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

A wound is described as damage and any disorder in the healthy structure and function of the skin. Wound healing is a complex and dynamic process that involves various types of cells, including leukocytes, blood cells, fibroblasts, and epithelial cells, as well as mediators, growth factors, and cytokines. The prolongation of wound healing results in chronic wounds with more severe wound conditions. Thus, therapeutic treatments involving bioactive healing agents and/or wound dressings, are employed to facilitate the healing process.

Marine organisms are increasingly important as a source of valuable biological active metabolites. In recent years, marine organisms have been proven to contribute a valuable chemodiversity and potential substance with medicinal properties, such as antioxidant, anti-inflammatory, antibacterials, and anticancer activity. Thus, marine organisms are the biggest source of positive natural compounds that could be utilized in the pharmaceutical industry as functional constituents.

Recently, there is a continuing increase in research targeting the discovery of compounds isolated from marine organisms that are effective for wound healing and skin tissue regeneration applications. The main goal of this Special Issue is to collect the original research articles regarding the wound healing effects of diverse marine organisms and marine natural products for development of cosmeceutical and/or biomedical materials.

Dr. Soo Jin Heo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Marine natural products
  • Bioactive compounds and bioactive peptides
  • Cosmeceutical materials
  • Biomedical potential
  • Wound healing
  • Skin cell migration
  • Anti-inflammatory
  • Antimicrobial
  • Fibroblast

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Article
The Marine-Derived Natural Product Epiloliolide Isolated from Sargassum horneri Regulates NLRP3 via PKA/CREB, Promoting Proliferation and Anti-Inflammatory Effects of Human Periodontal Ligament Cells
Mar. Drugs 2021, 19(7), 388; https://doi.org/10.3390/md19070388 - 09 Jul 2021
Cited by 4 | Viewed by 1905
Abstract
Currently, periodontitis treatment relies on surgical operations, anti-inflammatory agents, or antibiotics. However, these treatments cause pain and side effects, resulting in a poor prognosis. Therefore, in this study, we evaluated the impact of the compound epiloliolide isolated from Sargassum horneri on the recovery [...] Read more.
Currently, periodontitis treatment relies on surgical operations, anti-inflammatory agents, or antibiotics. However, these treatments cause pain and side effects, resulting in a poor prognosis. Therefore, in this study, we evaluated the impact of the compound epiloliolide isolated from Sargassum horneri on the recovery of inflammatory inhibitors and loss of periodontal ligaments, which are essential treatment strategies for periodontitis. Here, human periodontal ligament cells stimulated with PG-LPS were treated with the compound epiloliolide, isolated from S. horneri. In the results of this study, epiloliolide proved the anti-inflammatory effect, cell proliferation capacity, and differentiation potential of periodontal ligament cells into osteoblasts, through the regulation of the PKA/CREB signaling pathway. Epiloliolide effectively increased the proliferation and migration of human periodontal ligament cells without cytotoxicity and suppressed the protein expression of proinflammatory mediators and cytokines, such as iNOS, COX-2, TNF-α, IL-6, and IL-1β, by downregulating NLRP3 activated by PG-LPS. Epiloliolide also upregulated the phosphorylation of PKA/CREB proteins, which play an important role in cell growth and proliferation. It was confirmed that the anti-inflammatory effect in PG-LPS-stimulated large cells was due to the regulation of PKA/CREB signaling. We suggest that epiloliolide could serve as a potential novel therapeutic agent for periodontitis by inhibiting inflammation and restoring the loss of periodontal tissue. Full article
(This article belongs to the Special Issue Wound Healing Potential of Marine Natural Products)
Show Figures

Figure 1

Article
Chitosomes-In-Chitosan Hydrogel for Acute Skin Injuries: Prevention and Infection Control
Mar. Drugs 2021, 19(5), 269; https://doi.org/10.3390/md19050269 - 12 May 2021
Cited by 11 | Viewed by 2386
Abstract
Burns and other skin injuries are growing concerns as well as challenges in an era of antimicrobial resistance. Novel treatment options to improve the prevention and eradication of infectious skin biofilm-producing pathogens, while enhancing wound healing, are urgently needed for the timely treatment [...] Read more.
Burns and other skin injuries are growing concerns as well as challenges in an era of antimicrobial resistance. Novel treatment options to improve the prevention and eradication of infectious skin biofilm-producing pathogens, while enhancing wound healing, are urgently needed for the timely treatment of infection-prone injuries. Treatment of acute skin injuries requires tailoring of formulation to assure both proper skin retention and the appropriate release of incorporated antimicrobials. The challenge remains to formulate antimicrobials with low water solubility, which often requires carriers as the primary vehicle, followed by a secondary skin-friendly vehicle. We focused on widely used chlorhexidine formulated in the chitosan-infused nanocarriers, chitosomes, incorporated into chitosan hydrogel for improved treatment of skin injuries. To prove our hypothesis, lipid nanocarriers and chitosan-comprising nanocarriers (≈250 nm) with membrane-active antimicrobial chlorhexidine were optimized and incorporated into chitosan hydrogel. The biological and antibacterial effects of both vesicles and a vesicles-in-hydrogel system were evaluated. The chitosomes-in-chitosan hydrogel formulation demonstrated promising physical properties and were proven safe. Additionally, the chitosan-based systems, both chitosomes and chitosan hydrogel, showed an improved antimicrobial effect against S. aureus and S. epidermidis compared to the formulations without chitosan. The novel formulation could serve as a foundation for infection prevention and bacterial eradication in acute wounds. Full article
(This article belongs to the Special Issue Wound Healing Potential of Marine Natural Products)
Show Figures

Graphical abstract

Review

Jump to: Research

Review
Applications of Marine Organism-Derived Polydeoxyribonucleotide: Its Potential in Biomedical Engineering
Mar. Drugs 2021, 19(6), 296; https://doi.org/10.3390/md19060296 - 22 May 2021
Cited by 3 | Viewed by 3282
Abstract
Polydeoxyribonucleotides (PDRNs) are a family of DNA-derived drugs with a molecular weight ranging from 50 to 1500 kDa, which are mainly extracted from the sperm cells of salmon trout or chum salmon. Many pre-clinical and clinical studies have demonstrated the wound healing and [...] Read more.
Polydeoxyribonucleotides (PDRNs) are a family of DNA-derived drugs with a molecular weight ranging from 50 to 1500 kDa, which are mainly extracted from the sperm cells of salmon trout or chum salmon. Many pre-clinical and clinical studies have demonstrated the wound healing and anti-inflammatory properties of PDRN, which are mediated by the activation of adenosine A2A receptor and salvage pathways, in addition to promoting osteoblast activity, collagen synthesis, and angiogenesis. In fact, PDRN is already marketed due to its therapeutic properties against various wound healing- and inflammation-related diseases. Therefore, this review assessed the most recent trends in marine organism-derived PDRN using the Google Scholar search engine. Further, we summarized the current applications and pharmacological properties of PDRN to serve as a reference for the development of novel PDRN-based technologies. Full article
(This article belongs to the Special Issue Wound Healing Potential of Marine Natural Products)
Show Figures

Graphical abstract

Back to TopTop